Inspire Medical Systems, Inc. (INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will be presenting at the BofA Securities Virtual Health Care Conference 2020 on May 14, 2020. Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
Inspire Medical Systems, Inc. (NYSE:INSP) shareholders are probably feeling a little disappointed, since its shares...
Inspire Medical Systems (INSP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Inspire (INSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, NY / ACCESSWIRE / May 5, 2020 / Inspire Medical Systems, Inc. (NYSE:INSP) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on May 5, 2020 at 5:00 ...
One thing we could say about the analysts on Inspire Medical Systems, Inc. (NYSE:INSP) - they aren't optimistic...
BofA Securities, J.P. Morgan and Goldman Sachs & Co. LLC are acting as joint book-running managers for the proposed offering. The securities described above are being offered pursuant to an effective shelf registration statement that was filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 13, 2020. This offering will be made only by means of a prospectus supplement and the accompanying prospectus which forms a part of the effective shelf registration statement.
MINNEAPOLIS, May 05, 2020 -- Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative.
Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today the closing of its public offering of 2,300,000 shares of its common stock, at a public offering price of $58.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 300,000 additional shares. Guggenheim Securities and SVB Leerink acted as lead managers for the offering. The securities described above were offered pursuant to an effective shelf registration statement that was filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 13, 2020.
Inspire Medical Systems, Inc. (INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will be presenting at the virtual UBS Global Healthcare Conference on May 20, 2020. Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
MINNEAPOLIS, April 28, 2020 -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of.
Inspire Medical (INSP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
In addition, Inspire provided an update on the actions it is taking in response to the ongoing global COVID-19 pandemic. In line with recommendations from federal and local government and healthcare agencies, Inspire has transitioned employees, except for those deemed essential to key aspects of our business, to a remote work environment. During this interim period in which surgical procedures have been significantly limited, the Inspire team is identifying and implementing innovative solutions to support patients who have Inspire therapy, as well as continuing to educate patients who may be struggling with their sleep apnea.
Following a detailed review of the clinical evidence and iterative discussions with the FDA, Inspire believes that this is the initial step in the pediatric approval process, with further expansion to lower age groups possible. “We will conduct additional research on the specific characteristics of OSA in the pediatric population, including continuing the ongoing clinical study for adolescents with Down Syndrome.”
Inspire (INSP) delivered earnings and revenue surprises of 9.52% and 12.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Palmetto was the only remaining Medicare Administrative Contractor (“MAC”) to have not either issued its final LCD policy or set a release date. In addition to Palmetto, Inspire recently announced that Wisconsin Physicians Services (“WPS”) Government Health Administrators issued the effective date of June 14, 2020 for its final LCD.
Inspire (INSP) delivered earnings and revenue surprises of -17.54% and 0.03%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
INSP earnings call for the period ending March 31, 2020.
In addition, Inspire has granted the underwriters a 30-day option to purchase up to an additional 300,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The securities described above are being offered pursuant to an effective shelf registration statement that was filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 13, 2020. This offering is being made only by means of a prospectus supplement and the accompanying prospectus which forms a part of the effective shelf registration statement.